STOCK TITAN

Moderna (MRNA) SEC Filings

MRNA NASDAQ

Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.

Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.

Rhea-AI Summary

Moderna, Inc. (MRNA) amended its Credit and Guaranty Agreement with Ares Capital Corporation, as administrative agent and collateral agent, and participating lenders, effective November 9, 2026. The amendment reduces applicable interest rate margins for initial term loans and delayed draw term loans by 0.75 percentage points: from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate, and from 4.50% to 3.75% per annum for base-rate loans.

The amendment extends the maturity date for those loans from November 24, 2030 to November 24, 2031. It also extends availability for the first $400 million of delayed draw term loan commitments from November 24, 2027 to November 24, 2029, and for the remaining $500 million from November 24, 2028 to November 24, 2029. Both availability periods remain subject to earlier termination under the Credit Agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Moderna, Inc. officer Stephen Hoge reported a proposed sale of 39,160 common shares, with an aggregate market value of $8,601,863.46, for approximately November 16, 2026. The notice says the shares were acquired from the issuer through a stock option exercise, with cash payment, on November 16, 2026. It lists June 15, 2026 as the plan adoption or instruction date if relying on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Moderna, Inc. entered into a Transitional Services and Retirement Agreement with Chief Legal Officer Shannon Thyme Klinger. She will remain employed through March 31, 2027, unless the company designates an earlier date for her resignation from officer positions. Until then, she will continue to receive her current base salary and benefits and vest in outstanding equity awards; she is also eligible for a 2026 performance bonus based on her target bonus and the board-determined corporate performance factor.

The agreement provides for $1,628,300 in severance, paid in substantially equal biweekly installments over 12 months after her retirement date, and COBRA premiums through September 30, 2028, subject to earlier termination under specified conditions. Klinger is also eligible for $2,500,000 if Moderna prevails at the conclusion of all current and related future proceedings with Arbutus Biopharma Corporation and Genevant Sciences, GmbH, and for up to $5,500,000 subject to the results of current and related future proceedings with Pfizer, Inc., BioNTech SE and related parties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Moderna, Inc. (MRNA) Chief Operating Officer Juan Andres received 7,898 stock options and 16,955 restricted stock units on November 5, 2026. The options have an exercise price of $241.46 per share and expire November 5, 2036. For the options, 25% vests and becomes exercisable on November 5, 2027, with the remainder vesting in twelve equal quarterly installments thereafter. For the restricted stock units, 25% vests on that date, with the remainder vesting in twelve equal quarterly installments thereafter; each unit converts into common stock on a one-for-one basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
insider
-
Rhea-AI Summary

Moderna, Inc. reported third-quarter 2026 total revenue of $1.313 billion, compared with $1.016 billion a year earlier, and net income of $162 million versus a $200 million net loss. For the first nine months, revenue was $1.847 billion and net loss was $1.963 billion; operating cash outflow was $2.715 billion.

In Phase 3 INTerpath-001, intismeran plus KEYTRUDA reduced recurrence-or-death risk by 42% and distant-metastasis-or-death risk by 38% versus KEYTRUDA alone after a median 24.6-month follow-up. Overall-survival data were not yet mature, and the study remains ongoing.

Moderna issued $3.0 billion aggregate principal amount of 0.00% convertible notes due 2032 and received approximately $3.0 billion net proceeds; it paid $329 million for capped calls. It paid $950 million in July under its settlement with Arbutus and Genevant concerning worldwide litigation related to Spikevax and mRESVIA. After appealing the District Court's decision related to 28 U.S.C. § 1498, Moderna could be required to make an additional payment of up to $1.3 billion depending on the appeal outcome. Moderna launched mFLUSIVA in the U.S. in September after FDA approval for adults 50 years of age and older.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
quarterly report
-
Rhea-AI Summary

Moderna, Inc. reported third-quarter 2026 revenue of $1.313 billion, up 29% year over year, and net income of $162 million versus a $200 million loss a year earlier. Diluted EPS was $0.38 versus a $0.51 loss. Cash, cash equivalents and investments were $8.0 billion as of September 30, 2026.

For 2026, Moderna now expects revenue growth of 15%–25%, versus its previous outlook of up to 10%, and year-end cash and investments of $8.1–$8.3 billion, compared with its prior $4.7–$5.2 billion range. Expected R&D expense is approximately $2.7 billion, down from approximately $2.9 billion. September’s convertible notes offering had approximately $3.0 billion in principal and generated approximately $2.6 billion in net proceeds after capped calls and fees.

The FDA approved mFLUSIVA for adults aged 50–64 and granted accelerated approval for adults aged 65 and older; Moderna plans a limited U.S. launch for the 2026–2027 flu season. Phase 3 melanoma results for intismeran plus KEYTRUDA showed a 42% lower risk of recurrence or death versus KEYTRUDA alone. A norovirus vaccine Phase 3 interim analysis did not meet statistical criteria for early success, and Moderna does not plan an additional cohort this season. Moderna and GSK agreed to settle all pending U.S. and European disputes through patent cross-licenses, with no payments in connection with those licenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
current report
Rhea-AI Summary

FMR LLC reported beneficial ownership of 58,929,948 shares of Moderna, Inc. (MRNA), equal to 14.8% of the common stock. FMR LLC reported sole voting power over 58,374,818 shares and sole dispositive power over 58,929,948 shares. Abigail P. Johnson reported sole dispositive power over the same number of shares and no voting power. The report states that no other person's interest in the common stock exceeds 5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
ownership
-
Rhea-AI Summary

Moderna, Inc. President Stephen Hoge exercised options for 76,453 shares on October 14, 2026, and 76,452 shares on October 15, 2026, at an exercise price of $12.21 per share. On October 14, he sold 38,774 shares at a weighted average price of $213.47 and 450 shares at a weighted average price of $214.15. On October 15, he sold 39,145 shares at a weighted average price of $220.72.

The transactions were effected under a Rule 10b5-1 trading plan adopted June 15, 2026. Separate indirect-holding entries dated October 14 listed 4,116 shares held by Valhalla, LLC and 151,933 shares held by a trust for Hoge’s spouse and children, of which his spouse is a trustee. Hoge disclaimed Section 16 beneficial ownership of the trust shares except to the extent of any pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
insider
-
Rhea-AI Summary

Moderna, Inc. (MRNA) officer Stephen Hoge reported a proposed sale of 39,145 common shares on October 15, 2026, through Fidelity Brokerage Services LLC. The listed aggregate market value is $8,640,032.55. The notice also lists four prior sales between July 15 and October 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
other
Rhea-AI Summary

Moderna, Inc. officer Stephen Hoge reported a proposed sale of 39,224 common shares, with an approximate sale date of October 14, 2026, through Fidelity Brokerage Services LLC. The stated aggregate market value is $8,373,519.16, and NASDAQ is listed as the exchange. The shares are identified as acquired from the issuer through a stock option exercise for cash on October 14, 2026. Daniel Tucci signed as a duly authorized representative of Fidelity Brokerage Services LLC and as attorney-in-fact for Stephen Hoge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
other

FAQ

How many Moderna (MRNA) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Moderna (MRNA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Moderna (MRNA)?

The most recent SEC filing for Moderna (MRNA) was filed on November 16, 2026.